Literature DB >> 24989696

Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Prasad S Adusumilli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24989696      PMCID： PMC4448967          DOI： 10.1002/cncr.28883

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  24 in total

Review 1.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

2.  Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Authors:  Elliot L Servais; Christos Colovos; Luis Rodriguez; Adam J Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W Rusch; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

3.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Authors:  Michelle Hong; Anne-Laure Puaux; Caleb Huang; Laure Loumagne; Charlene Tow; Charles Mackay; Masashi Kato; Armelle Prévost-Blondel; Marie-Françoise Avril; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

4.  A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.

Authors:  B C John Cho; Ron Feld; Natasha Leighl; Isabelle Opitz; Masaki Anraku; Ming-Sound Tsao; David M Hwang; Andrew Hope; Marc de Perrot
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

5.  Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.

Authors:  Stefan S Kachala; Adam J Bograd; Jonathan Villena-Vargas; Kei Suzuki; Elliot L Servais; Kyuichi Kadota; Joanne Chou; Camelia S Sima; Eva Vertes; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

6.  Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

Authors:  Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Michel Sadelain; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-07-19       Impact factor: 6.968

7.  Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.

Authors:  Raffit Hassan; Andrew C Miller; Elad Sharon; Anish Thomas; James C Reynolds; Alexander Ling; Robert J Kreitman; Markku M Miettinen; Seth M Steinberg; Daniel H Fowler; Ira Pastan
Journal:  Sci Transl Med       Date:  2013-10-23       Impact factor: 17.956

8.  Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.

Authors:  Nabil P Rizk; Elliot L Servais; Laura H Tang; Camelia S Sima; Hans Gerdes; Martin Fleisher; Valerie W Rusch; Prasad S Adusumilli
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

Review 9.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

10.  A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Authors:  John E Weldon; Laiman Xiang; Jingli Zhang; Richard Beers; Dawn A Walker; Masanori Onda; Raffit Hassan; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2012-11-06       Impact factor: 6.261
View more
  4 in total

1.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Authors:  Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

Review 2.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

Authors:  Aurore Morello; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Discov       Date:  2015-10-26       Impact factor: 39.397

3.  Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Authors:  Xiaoyu Li; Takashi Eguchi; Rania G Aly; Navin K Chintala; Kay See Tan; Marjorie G Zauderer; Francine R Dembitzer; Mary Beth Beasley; Berhane Ghebrehiwet; Prasad S Adusumilli; Ellinor I B Peerschke
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

4.  gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.

Authors:  Ellinor Peerschke; Kenneth Stier; Xiaoyu Li; Evelyn Kandov; Elisa de Stanchina; Qing Chang; Yuquan Xiong; Katia Manova-Todorova; Ning Fan; Afsar Barlas; Berhane Ghebrehiwet; Prasad S Adusumilli
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.